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Abstract
Research & Development (R&D) plays an increasingly important role in China’s pharmaceutical industry. To gain a 
competitive edge in the global pharmaceutical market, the current national strategy of China forcefully pushes for 
independent drug innovations. This article investigates the historical, legal, and institutional contexts in which China’s 
drug R&D has evolved. Based on an analysis of the drug R&D evolution and national policies in China, it predicts the 
future trend of China’s policies relevant to drug innovations. This paper helps to understand the impact of national 
policies on drug R&D in China, which can be used to inform decision-making on investments in China’s pharmaceutical 
market or conducting technology trade and international cooperation with Chinese partners.  
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Introduction
China’s pharmaceutical industry has developed rapidly 
with its booming economy. Since China’s reform and 
opening-up in 1978, the pharmaceutical industrial output 
value has been increasing at an average annual growth 
ratio of 16.6%. Along with this remarkable growth, China’s 
pharmaceutical industry has switched its focus of drug 
discovery from imitation to innovation so that its drug 
products are more competitive in the global market.
Drug R&D is a risky business characterized by large 
investments, long duration, low success ratios, and high 
technical spillover (Li, 2007). While a number of ways 
can be employed to spur drug R&D, the experience 
of developed countries indicates that government 
regulations, incentives, and policies play a prominent role 
in augmenting a country’s drug R&D capabilities (Du, 
2005). The Chinese government has been deeply involved 
with nurturing its drug R&D capabilities by creating an 
innovation-oriented environment. National policies have 
inevitably shaped the evolution path of China’s drug R&D. 
Bartlett and Ghosal (2000) created the pharmaceutical 
industry value curve to help understand how companies 
evolve into certain product segments. The pharmaceutical 
product market can be viewed as a collection of segments: 
some are more profitable than others. To compete in the 
more profitable segments requires more sophisticated and 
complex R&D capabilities. As technological complexity 
of a product segment increases, its gross margin is 
enlarged. When companies have no capabilities to deal 
with technologically complex products, they have to stay 
at the lower end of the curve. Once they are capable of 
developing more complex products, they are likely to 
move up the curve to enter a more profitable segment. 
The pharmaceutical industry value curve is consistent 
with the knowledge-based view of firms which posits that 
knowledge is the most important organizational asset 
determining superior firm performance (Grant, 1996). 
Based on the pharmaceutical industry value curve and a 
case study, this article intends to answer two research 
questions: (1) how China’s drug innovation evolved and 
(2) what are China’s current national strategy and policy 
systems that influence its drug innovation? It investigates 
the historical, legal, and institutional contexts in which 
China’s drug R&D have taken place. Based on an analysis of 
the evolution of drug R&D, and incentive policy systems of 
IPR in China, it predicts the future trend of drug innovation 
policies in China. It provides a rich understanding of the 
national policies relevant to drug innovations, which can 
be used to help developing countries design appropriate 
policies to motivate drug innovations and help companies 
make decisions on investing in China’s pharmaceutical 
market or conducting technology trade and international 
cooperation with Chinese partners.
The following section describes the methodology of this 
study. At first the methodology is described. The results are 
reported next – specifically, the phased evolution of drug 
innovation in China, the R&D level and important policies 
in each phase, and the national drug innovation strategy and 
policy system are described and analyzed. In the discussion 
section, we discuss China’s policy trends relevant to drug 
innovation. Finally, the conclusion section ends the paper.
Methods
Given the descriptive and exploratory nature of this 
study, we employed a qualitative research method 
to collect secondary data (Yin, 2003). The data were 
collected from four sources to obtain a complete set of 
information regarding China’s drug R&D evolution. First, 
we collected official data from government reports and 
databases including the China Medicine Yearbook, China’s 
Advanced Technology Industry Census, China’s Science 
and Technology Statistics, annual reports of the State 
Food and Drug Administration of China (SFDA) and Food 
and Drug Administration of the United States (FDA), and 
patent databases of State Intellectual Property Office of 
China (SIPO), United States Patent and Trademark Office 
(USPTO), Japan Patent Office (JPO), and European Patent 
Office (EPO). Second, we retrieved relevant information 
by searching industrial databases including China’s 
Medicine Economics Information Network, European 
Federation of Pharmaceutical Industries and Associations 
(EFPIA), Pharmaceutical Research and Manufacturers 
of America (PhRMA), and Japan Pharmaceutical 
Manufacturers Association (JPMA). Third, we reviewed 
all of the laws, regulations, and national policies related 
to pharmaceuticals, patents, and science and technology 
from 1991 to 2009. Finally, we downloaded documents 
from a number of pharmaceutical companies from which 
the evolution of China’s drug R&D can be inferred. The 
data gathered from different sources were integrated 
along the timeline of China’s R&D evolution. 
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Since the majority of the data we collected are not 
structured, it was difficult to search the data using specific 
keywords. Instead, two authors read all of the documents 
to retrieve information on drug-related R&D, innovation, 
patent, intellectual property, regulations, laws, and 
policies. The information was organized in a chronological 
order. Charts were drawn to show the major events, key 
statistics and relevant laws and policies along a time axis. 
Using the pharmaceutical industry value curve (Bartlett & 
Ghosal, 2000) as a framework, the authors defined drug 
R&D phases through individual reflection on the data and 
several rounds of debates until agreement was achieved. 
Once the phases were determined, we organized the data 
into each phase and examine how the phase was charac-
terized by the key events that occurred in that period. 
Applying the triangulation strategy (Yin, 2003), we used 
duplicate information sources to confirm the validity of 
the event information. Given the descriptive nature of 
this study and the lack of control over confounding fac-
tors, we did not try to draw causal relationships between 
events during data analyses. The analyses were focused 
on creating a precise account of China’s drug R&D evolu-
tion and the relevant institutional context. 
Results
Evolution of China’s Drug Innovation
Based on the pharmaceutical industry value curve (Bart-
lett & Ghosal, 2000) and prior research into China’s drug 
innovation (Lin, 2007; Zhang et al., 2009), China’s drug 
R&D evolution can be viewed to have four phases. Fo-
llowing Liang et al. (2011), we label these four phases as: 
(1) pure imitation, (2) innovative imitation, (3) imitative 
innovation, and (4) independent innovation. Please note 
that this analysis is based on Western medicine and does 
not include traditional Chinese medicine. In Phase I, pure 
imitation, the pharmaceutical firms fully depended on co-
pying synthetic methods and preparation technologies of 
drugs from foreign companies. In Phase II, innovative imi-
tation, China’s drug innovation was mainly based on mo-
difying delivery methods and preparation formulations of 
existing drugs without changing the drug molecular struc-
ture. In Phase III, imitative innovation, drug innovation 
was focused on chemical modifications of the structure 
of existing drugs, such as changing acid or basic group, 
altering optical configuration, and developing isomers of 
original drugs to develop “me-too” drugs.  Finally, in Pha-
se IV, independent innovation, Chinese companies will be 
able to discover new chemical entities (NCEs) using ad-
vanced innovation technologies. 
As the drug R&D and the IP policies have coevolved in 
China, the dates when different patent laws came into 
force can be used as ideal timeline anchors to delimit 
the four phases. As Table 1 shows, China enacted three 
patent laws in 1985, 1992, and 2008, respectively. Befo-
re 1985, China’s pharmaceutical companies could legally 
copy any drugs from foreign countries. After the 1985 
patent law which protected manufacturing processes of 
drug synthesis and dosage forms, companies could still 
imitate existing drugs, but they had to conduct low-level 
innovations to develop new synthesis methods or new 
dosage forms. Since the1992 patent law started to grant 
full patent protection to drugs, the pharmaceutical com-
panies could not imitate existing drugs without modifying 
their molecular structures. Thus, after 1992, they focused 
on developing “me-too” drugs which have minor structu-
ral differences from existing drugs. After the 2008 patent 
law entered into force, drug patent protection in Chi-
na became more comprehensive and stronger, making it 
difficult to imitate existing drugs. Hence, in this period 
the best way for pharmaceutical companies to stay com-
petitive would be to conduct independent innovations by 
discovering NCEs.
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Phase 
Patent law amendment 
date 
IP protection for drugs 
Pure imitation (1949 – 1985) n/a n/a 
Innovative imitation (1984 – 1993) March 12,1984 
Protection of the synthesis and 
dosage form manufacturing 
processes of pharmaceuticals only 
Imitative innovation (1992 – 2008) September 4,1992 Patent protection of drugs 
Independent innovation (2008 – ) December 27, 2008 
Patent exemption for drugs trail 
compulsory licensing and parallel 
import of patent drugs 
 Table 1. Evolution of China’s Intellectual Property Protection for Drugs
Phase I: Pure Imitation (1949 – 1984)
In 1949, China had approximately 150 small pharmaceuti-
cal factories, which could manufacture only over 40 types 
of drugs in small scales. Lacking production capacity and 
technologies, China could not even independently supply 
the six basic types of medicines: antibiotics, sulfonami-
des, antipyretic drugs, vitamins, endemic drug, and anti-
tuberculosis. In addition, China’s pharmaceutical educa-
tion was seriously underdeveloped. There was only one 
pharmaceutical college and a few pharmacy departments 
in medical colleges.
The Chinese government took a strategy of pure imi-
tation and import to sustain the nation’s fundamental 
medication needs. Pharmaceutical factories were en-
couraged to imitate patent drugs from foreign countries 
by reverse engineering and focus on expanding the phar-
maceutical synthesis capacity. Meanwhile, the govern-
ment allocated funds to establish of several large-scale 
state-owned pharmaceutical enterprises to produce an-
tibiotics, sulfonamides, and antipyretic analgesics. While 
setting the focus on manufacturing bulk drugs, the go-
vernment gave priority to the R&D of antibiotics, sulfo-
namides, and other medicines which were widely used 
for preventing endemics and epidemics and desperately 
needed in rural regions. In the 1960s, a centralized lea-
dership for the pharmaceutical industry was implemen-
ted, and under its guidance China’s domestic pharma-
ceutical industry started to develop in a planned manner. 
After over 30 years development, China’s pharmaceuti-
cal industry became much stronger. In 1985, there were 
1,377 domestic pharmaceutical manufacturers in Chi-
na, which hired 522,600 employees and created a gross 
output value of $1.56 billion. The total output of chemical 
medicines was 5.76 ton, achieving a profit tax of $0.26 
billion and a sales amount of one billion dollars. The phar-
maceutical production capacity could basically satisfy the 
domestic demand. Bulk drug manufacturing bases were 
firmly established and a great amount of experts and pro-
fessionals in chemical synthesis were cultivated.
Before 1985, China had no patent law to protect IP rights 
of pharmaceutical products. The whole pharmaceutical 
industry was unaware of the importance of drug inno-
vation. Almost all pharmaceuticals were directly copied 
from foreign companies.
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Moreover, China’s drug R&D investment was far less than 
that of developed countries. For example, in 1985 the 
drug R&D expenditures in the U.S. were over $3.3 billion, 
more than the total investment of science and technology 
innovations in China ($3.1 billion). In spite of 32 phar-
maceutical research institutions and 5,692 researchers, 
China’s overall drug innovation capability was insufficient 
for conducting advanced drug R&D and far behind deve-
loped countries. In 1985, China had no universally recog-
nized new chemical entity (NCE), whereas 26 NCE drugs 
were approved in the U.S. 
Phase II: Innovative Imitation (1985 – 1993)
China started IP protection by enforcing its first patent 
law on April 1, 1985. Along with the Drug Administration 
Law and the Trademark Law, the basic policy system for 
drug IP protection came into being. Meanwhile, in order 
to encourage innovations in the pharmaceutical industry, 
the Chinese government carried out a series of major 
national investment projects, such as the Spark Plan and 
the 863 Program, to give enterprises financial support for 
technology innovations. National policies also created a 
facilitating environment for pharmaceutical innovations. 
For example, “Provisional Regulations of the National 
Hi-tech Industry Development Zone Policies” (1991) 
provided tax benefits to hi-tech companies, including 
pharmaceutical companies. 
With the establishment of an IP legal system, Chinese 
pharmaceutical companies started to realize the 
importance of innovations, and gradually increased R&D 
investments. In this phase, the major approach to drug 
innovation was still based on imitating existing drugs. 
Different from pure imitation, some innovative features 
were added so that the new product was not a direct copy 
of the original drug. Yet these innovations are at a low level, 
mainly focused on drug delivery methods and preparation 
formulations. The new drug’s molecular structure was 
exactly the same as that of the original drug. This was 
because (1) most Chinese companies lacked technology, 
experience, and capital to develop more advanced 
innovations, and (2) the Chinese IP policy did not prohibit 
imitating the molecular structure of existing drugs. 
In this phase, the number of new drug approvals increased 
dramatically every year (Figure 1). While in 1986 less 
than five new drugs were approved, 205 new drugs were 
approved in 1992. Although several Class-I drugs were 
approved every year, since China had a lower standard 
than the global standard, only one drug, artemisinin, was 
internationally recognized as a NCE.
 
!
Figure 1. Numbers of new drug approvals from 1986 to 1992 (Source: Chinese Medicine Yearbook)
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Phase III: Imitative Innovation (1993 – 2008)
To comply with TRIPS and prepare for entering the 
WTO, China amended its Patent Law in 1993 and 2000 
respectively and revised the “Detailed Rules for the 
Implementation of the Patent Law” accordingly. These 
legislative changes signified China’s strong IP protection. 
China’s Patent Law provided protection for medical 
products, process, and products obtained by the patented 
process. The term of patent protection for a new drug is 
20 years since the day of filing, during which no entity or 
individual may, without the authorization of the patentee, 
exploit the patent for production or business purposes.
To comply with TRIPS, the Trademark Law, amended in 
the year 1993 and 2001 respectively, provides a validity 
period of ten years for a registered trademark. Where 
the registrant intends to continue to use the registered 
trademark beyond the expiration of the validity period, 
an application for renewal of the registration shall be 
made within six months before the said expiration. The 
validity period of each renewal of registration shall be ten 
years. Though drugs are not compelled to have registered 
trademarks any more, the “well-know trademark” and 
“geographical indications” specified in the newly-amended 
Trademark Law offer strong protection for the sales of 
new drugs. For example, compound radix pseudostellariae 
granule is developed from radix pseudostellariae, a natural 
product whose quality is the highest in Tuorong County 
in Fujian Province and geographical indications have 
provided strong protection for its sales against similar 
products from other regions (Pan & Chen, 2009).
The Pharmaceutical Administration Law amended in 2001 
and Provisions for Drug Registration have legally defined 
new drug for the first time1 . They offer Data Exclusivity 
Protections to the applicant who obtains approval for 
production or distribution of the drug which contains any 
new chemical entity2.
During this period, the Chinese government implemented 
the 973 Project and National Science and Technology 
Major Project3 successively to encourage technology 
innovations. In addition, a series of tax exemption policies 
were enacted to spur technology innovations through 
reducing income taxes, value-added taxes, and business 
taxes related to technology innovations.



















1Article 12(1),(2) of Provisions for Drug Registration: Application for new drugs refers to the application for registration of drugs that has 
not been marketed within the territory of People’s Republic of China. Application for changing dosage form or route of administration, 
or claiming a new indication for marketed drugs, shall be submitted as the process of new drug application. 2Article 20 of Provisions for 
Drug Registration: In accordance with the provisions in Article 35 of the Regulations for Implementation of the Drug Administration Law, 
where a manufacturer or distributor submits undisclosed drug experimental and other data which are independently acquired in order 
to obtain approval for production or marketing of the drug in question which contains any new chemical entity, the State Food and Drug 
Administration shall, within six years from the approval date of the drug, reject any application made by any other applicants by using the 
undisclosed data of the drug in question without permission of the original applicant who has obtained the drug approval, unless the data 
submitted are independently acquired by the applicants other than the original one. 3 The National Science and Technology Major Project 
was confirmed in the National Program for Medium-term and Long-term Science and Technology development in January 2006 with special 
emphasis on 16 major projects, including major new drugs creation, control and prevention of major infectious disease.
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During this period, China’s drug production capacity 
was improved greatly with the output value of the 
pharmaceutical industry increased from $373 billion in 
2003 to $1220 billion in 2008. The pharmaceutical industry 
in China has demonstrated an accelerating development 











            
 
in controlling bribes in pharmaceutical sales and rectifying 
the market order and a wave of drug price drop (Lu, 
2006), the industry’s growth ratio had a sudden decline in 
2006. Nonetheless, the output value of 2006 is still about 
15% more than that of 2005 (see Figure 2).
Figure 3. Volume of new drug approvals and patent applications filed from 1994 to 2007 (Source：China medicine yearbook)
As the market became increasingly globalized, Chinese 
enterprises fully realized the significance of innovations 
and made great improvement in drug R&D capabilities. 
The number of new drugs marketed in 2007 is ten times 
as many as that in 1994. Although the high volume of new 
drug approvals (NDAs) indicates China’s awareness of 
the importance of drug innovation, it should be noted 
that the volume itself cannot reflect China’s real drug 
innovation capabilities because serious corruptions of 
the State Food and Drug Administration (SFDA) and 
China’s low standard for new drugs contributed to the 
high volume (Liang et al., 2011). As shown by Liang et al. 
(2011), if the new drug standards of the United States are 
applied, China had only two NCEs from 2000 to 2008, 
while the United States had 193 NCEs in the same period. 
Since the new “Provisions for Drug Registration” was 
enacted on October 1st 2007, the SFDA had raised the 
entry threshold for drug registration and tightened the 
new drug approval standards, which greatly reduced the 
number and improved the quality of new drugs (Wang, 
2009). As Figure 3 shows, the number of new drug 
approvals declined drastically from over 12,000 in 2006 to 
less than 5000 in 2007. The number of patent applications 
has been rising continuously with the improvement of the 
patent law. For instance, the number of applications in 
2007 is over 200 times more than that in 1994. However, 
the amount of Class-I new drugs comparable to NCEs is 
rather low, just accounting for 6% of all the new drugs 
approved in 2007.
Phase IV: Independent Innovation (2008 – present)
 
In 2008, China’s drug R&D expenditure was approximately 
$1.57 billion and 37,200 R&D personnel were involved. 
Compared with developed countries, however, China’s 
drug R&D input is still at a low level. In 2008, China’s R&D 
investment accounted for 1.33% of sales revenues, while 
USA, European Union (EU) and Japan spent more than 
13% of sales revenues. R&D personnel in those developed 
countries also outnumbered those in China. For input in 
drug R&D, there is still a large gap between China and the 
developed countries (see Table 2).
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 China America EU Japan 
Sales value Billion dollars  117.91 286.01 247.36 77.30 
R&D input Billion dollars  1.57  38.43 37.81 14.88  
R&D input / Sales value 1.33% 13.44% 15.28 % 19.24% 
Developers 37241  700000 117000  
 Table 2. Comparison of R&D input between China and developed countries in 2008  (Sources: EFPIA, PhRMA, JPMA, China’s high-tech 
industrial statistics yearbook))/ * Based on the measurement results of the average growth rate of pharmaceutical R&D expenditure in America, 
EU, Japan and China in 2000-2007
The SFDA received 165 new drug applications in 2008 
most of which were formulation changing or dosing route 
changing of marketed drugs. Due to different definitions 
of new drug, the number of new drug applications in China 
is almost the sum of applications filed in EU, Japan, and 
U.S. in 2008. But EU and U.S. independently developed 
far more NCEs than China (Table 3). In 2008, China only 
had one NCE, laprazole, an agent to treat peptic ulcer. At 
present, China’s drug R&D capabilities still seriously lag 
behind developed countries. In addition, in 2008 the State 
Intellectual Property Office (SIPO) of China received 
9259 drug patent applications, more than those in EU 
and U.S., suggesting the heightening of awareness of IP 
protection in China.
 China USA Japan EU 
New drug applications 165 31 77 66 
NCE 1 21 3 6 
Drug patent applications 9259 5051 8962 6041 
 
Table 3. Comparison of drug R&D output between China and developed countries (Source: Annals of FDA, EMEA, PMDA, SFDA in 2008, 
USPTO, EPO, JPO, SIPO, China’s patent database)
National drug innovation strategy and policy
The national innovation policies with the core of the 
IPR policy have played an important role in guiding 
China’s drug R&D. Prior research shows that a nation’s 
drug innovation level and its relevant policies mutually 
influence each other (Ding & M, 2009; Yang et al., 2007; 
Zhang et al., 2008). The basic principle of China’s drug 
innovation policy is embodied in two fundamental national 
strategies: building an innovative country and establishing 
intellectual property rights. In 2006, the 17th National 
Congress of Chinese Communist Party emphasized 
that enhancing independent innovation capabilities 
and constructing an innovative country are the core of 
China’s national development strategy, which are crucial 
for improving China’s comprehensive national power. 
This is the first time the Chinese government includes 
the concept of innovation in its national development 
strategy. In 2008, the Chinese State Council issued 
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“National Intellectual Property Strategy Compendium”, 
asserting that China would be transformed into a 
country with high level of creating, utilizing, protecting 
and administrating intellectual properties by 2020. 
China’s national drug innovation policy system consists of 
relevant laws, regulations and policies promulgated under 
the national strategy, which is intended to stimulate 
independent drug innovations. Based on different executing 
agencies and mechanisms of policy tools, this system can 
be described as having three major components: the core 
IPR policy, the drug regulatory policy, and other related 
national policies (Figure 4).
 
The Core IPR policy 
Drug regulatory policy 
Other related policies 
Patent review and approval  
Patent administration  
Patent protection  
Drug regulatory approval  
Drug pricing  
Compensation of essential medicines 
Scientific and technological input policy 
Tax incentive policy 
Monetary policy 
Venture capital policy 
Research incentive policy 
China’s policy 
system for drug 
innovation 
Figure 4. China’s policy system for drug innovation
Core Intellectual Property Policy 
The core IP policy is a collection of laws and regulations 
on IPR. The state IP office and its branches are the main 
executing agents (Liu, 2009). The legal system of IP in China 
includes patent, trademark and copyright laws, among 
which the patent law (the new patent law enacted on 
October1, 2009) is the most influential one on drug R&D.
The new patent law adopted the international standard 
of novelty examination to conduct drug patent review 
and approval so that innovative drugs made in China 
are competitive in the global market. In terms of drug 
patent administration, new clauses of parallel importing, 
compulsory licensing and drug trail and application 
exemption (Bolar exception) are added. To enforce 
drug patent protection, the new patent law increased 
administrative penalties for patent violations. Temporary 
injunctions before a lawsuit of patent infringement are 
also specified by the law to provide stronger protection 
for the IPR owner’s benefits. 
 
Drug regulatory policy
China’s drug regulatory policy centers on Drug 
Administration Law and Provisions for Drug Registration. 
Its objective is to ensure drug safety, efficacy, quality 
and accessibility. The State Development and Reform 
Commission (SDRC), SFDA and their branches are the 
main executing agents. Given the significant impact of 
drugs on national health care, strict regulatory policies 
have been formulated to control the market approval and 
pricing of drug products. While strict procedures and 
criteria are set by law to review and approve new drugs, 
the Chinese government opens a special “green channel” 
for new drugs independently developed by domestic 
organizations and orphan drugs to shorten the review time.
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SDRC promulgated the Drug Pricing Measures (draft), 
which proposes higher prices for patented drugs than 
generic drugs. The purpose is to help firms get return 
on investments in drug R&D. Besides, according to the 
draft implementation of national essential drugs policy, 
new drugs with better cost-effectiveness are planned to 
be added into the National Essential Drugs List, so the 
inventing pharmaceutical companies can be compensated 
for their R&D investment. However, it should be noted 
that drug pricing is a complicated issue and could distort 
market incentives and inappropriately reward physicians’ 
overprescribing (Sun et al., 2008).
Other related policies
The Chinese government has implemented a series of 
policies in various areas such as science and technology 
input and tax preference to encourage technology 
innovations in the pharmaceutical industry. Aiming to 
realize the national strategy of improving the capability 
of independent innovation and building an innovative 
country, the Chinese government has activated a national 
program, Major New Drug Creation, proposing a 
budget of almost one billion dollars to support domestic 
pharmaceutical companies to develop new drugs with 
independent IPR. The government has been steadily 
increasing funding to support drug R&D activities of the 
domestic pharmaceutical industry. For example, the large 
pharmaceutical firms’ R&D expenditures supported by 
the government increased from about $125,000 in 2002 
to $313,000 in 2007. In addition, the Chinese government 
applied tax reduction for high technology industry, 
including pharmaceutical industry. Pharmaceutical firms 
are eligible for exemption of income and sales taxes for 
their drug R&D expenses.
Discussion
The results suggest that China’s national policies have 
played a significant role in developing an innovation-
friendly context within which the nation’s drug innovation 
capabilities are expected to be fostered. An in-depth analysis 
reveals five trends of China’s drug R&D environment.
Balance between patent and accessibility 
Although new drugs are discovered to help human beings 
counter health threats, these new drugs are usually 
protected by IPR and too expensive for people with an 
ordinary income. The Chinese government has realized 
the paradox and started to alleviate this problem through 
policy adjustments. The clauses of compulsory licensing 
and drug trail exemption in the new patent law are the 
first steps taken in this direction. China is also reforming 
its essential drug list to ensure that the public has access 
to basic medicines. 
Stricter drug review process 
SFDA disclosed at the beginning of 2009 that the principle 
of its future drug review and approval work would be to 
use strict standards to identify innovative and high quality 
drugs. In the past, SFDA had limited technical capacity 
to ensure the quality of NDAs. To remove loopholes 
in original data verification and production process 
inspection, the “Provisions for Drug Registration” 
requires that new drug R&D should be under whole 
process monitoring and the authenticity, accuracy and 
completeness of original records should be confirmed on-
site (Zhao et al., 2009). The government will continue to 
enforce effective drug administration with strict review 
and approval procedures, which is expected to guide 
pharmaceutical companies to form a scientific attitude 
towards drug R&D and increase drug quality. 
Shorter drug approval time  
 Time required for clinical trials and drug approvals in 
China is expected to become shorter. From the early 
1990s to the early 2000s, the average time for clinical 
trials declined from 79.5 to 63.2 months, and the average 
time for drug approval dropped from 31.3 to 18.4 months 
(Wang & Kang, 2005). At present，the NDA approval 
duration is from 12 to 18 months (Chenoweth, 2005). 
SFDA will continue to improve the mechanism of drug 
review and approval in the coming years by increasing 
review efficiency and communications between applicants 
and the approving agency.
Heavier government investment 
To accelerate the implementation of the strategy of 
building an innovative country, the NDRC issued the 
Eleventh Five-Year plan which is focused on developing 
China’s fundamental capacity of independent innovation. 
As a special project under the umbrella of the Eleventh 
Five-Year plan, Major New Drug Creation aims to 
develop a series of innovative drugs for 10 major 
diseases such as malignant tumors and cardiovascular 
diseases with a budget of about US$1 billion. It is 
expected to greatly improve the innovation capability 
of China’s pharmaceutical industry. The 12-year project 
was officially started in May 2008 and includes three 
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phases. It is estimated that the funding for this project 
will increase from $1 billion to about $4.3 billion by 2020 
(Ren, 2009). The Chinese government is determined 
to strengthen its drug innovation by pouring financial 
resources and this trend will continue for years to come.
More extensive regional integration
At present, China’s pharmaceutical industry is characterized 
by small companies scattered in many regions, leading 
to insufficient resource sharing and cooperation and 
inadequate integration of competencies within districts. 
In 2009, China has 4881 drug manufacturers that produce 
more than 12,000 categories of medicines and many 
of their products are low-level duplicates. Regional 
agglomeration of the pharmaceutical industry can help 
to solve these problems and it is also conducive to 
attracting specialized talents and venture capital needed 
by R&D (Mao, 2006). The Chinese government has issued 
a series of policies such as financial support and tax 
preference offered to major innovation projects within 
pharmaceutical industrial clusters. At the end of 2007, the 
SDRC issued national proposals to guide the development 
of industrial clusters. Responding to the SDRC proposal, 
many regional biopharmaceutical industrial cluster 
development plans and biopharmaceutical technology 
parks have been developed. The technology parks have 
demonstrated healthy growth. In the next few years, more 
pharmaceutical industrial clusters are expected to emerge.
Conclusion
This study shows that drug innovation in China has 
evolved from pure imitation to a stage where independent 
innovation is desirable and possible. During the course 
of evolution, the government has played a significant 
role by issuing various policies, laws, and strategies to 
cultivate and spur the domestic drug R&D. A valuable 
lesson for other developing countries is that in order to 
improve drug innovation capabilities the government has 
to get highly involved. Without an innovation-friendly 
policy environment, drug innovation will be difficult to 
prosper. Moreover, this study presents a detailed account 
of China’s policy system relevant to drug innovation. 
With an understanding of the complex policies and their 
implications for drug R&D, international investors will 
be able to make better informed decisions when they 
attempt to operate pharmaceutical businesses in China. 
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